No Data
No Data
EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe V. Wade Overturn, CEO Says
Femasys Inc (NASDAQ:FEMY) is a biomedical company focused on women's healthcare.The company, with a market capitalization of $22.50 million as of data from Benzinga Pro on 17 June, went public in June
Femasys Is Putting Women in Charge of Their Reproductive Health
Femasys's Buy Rating Affirmed by Analyst Jason McCarthy on FemaSeed's Market Success and Robust Clinical Trials
Express News | Femasys Inc : H.c. Wainwright Raises Target Price to $13 From $12
Express News | HC Wainwright & Co. Reiterates Buy on Femasys, Maintains $13 Price Target
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK) and Femasys (FEMY)
No Data
71863268 : watch and learn
that's how
HH1000OP 71863268: thats helpful..thanks